Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Resectable Lung Non-Small Cell Carcinoma: full-pipeline trial registry
2 of 2 indexed Resectable Lung Non-Small Cell Carcinoma trials are currently recruiting.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count
Resectable Lung Non-Small Cell Carcinoma: 2 US clinical trials tracked, 2 recruiting.
Resectable Lung Non-Small Cell Carcinoma is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Alliance for Clinical Trials in Oncology, running 1 of these trials.
Enrollment posture brief
Registry condition resectable-lung-non-small-cell-carcinoma
OPEN 2 | RECR 100% | LATE 1 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Resectable Lung Non-Small Cell Carcinoma lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Resectable Lung Non-Small Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Resectable Lung Non-Small Cell Carcinoma is recruiting above its size-band peers.
2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
NCT06632327
Proton Beam Radiation Therapy After Treatment for Resected N2 Non-Small Cell Lung Cancer
Emory University
NCT06008730
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Resectable Lung Non-Small Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Resectable Lung Non-Small Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Resectable Lung Non-Small Cell Carcinoma page
2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Resectable Lung Non-Small Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Alliance for Clinical Trials in Oncology sponsors the most Resectable Lung Non-Small Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See Alliance for Clinical Trials in Oncology's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Resectable Lung Non-Small Cell Carcinoma condition card totals 2 registered trials; most-linked intervention Radiology, Treatment Planning; top US site state Georgia. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.